AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 373358 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 38
Study 6404954 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg three times a day
Number of subjects: 30
Study 6404954 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 30
Study 6404954 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 30
Study 6404954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29843899 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) 24 Gy
Number of subjects: 55
Study 29843899 — intervention group
Group type: COMPARATOR
Intervention: Three-dimensional conformal radiotherapy (3DCRT) 30 Gy in 10 fractions
Number of subjects: 55
Study 27590568 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic morcellation with the TRUCLEAR 8.0 Tissue Removal System
Number of subjects: 86
Study 27590568 — intervention group
Group type: COMPARATOR
Intervention: Loop resection with a rigid 8.5‐mm bipolar resectoscope
Number of subjects: 86
Study 27590568 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic morcellation
Number of subjects: 86
Study 27590568 — intervention group
Group type: COMPARATOR
Intervention: Loop resection
Number of subjects: 86
Study 25193531 — intervention group
Group type: EXPERIMENTAL
Intervention: Gla‐300 (insulin glargine 300 units/mL)
Number of subjects: 811
Study 25193531 — intervention group
Group type: COMPARATOR
Intervention: Gla‐100 (insulin glargine 100 units/mL)
Number of subjects: 811
Study 25193531 — intervention group
Group type: EXPERIMENTAL
Intervention: Gla‐300
Number of subjects: 811
Study 22476616 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 370
Study 22476616 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylureas
Number of subjects: 370
Study 22476616 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosidase inhibitors
Number of subjects: 370
Study 22476616 — intervention group
Group type: EXPERIMENTAL
Intervention: Glinides
Number of subjects: 370
Study 22476616 — intervention group
Group type: EXPERIMENTAL
Intervention: Glitazones
Number of subjects: 370
Study 22476616 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitors
Number of subjects: 370
Study 22476616 — intervention group
Group type: COMPARATOR
Intervention: Hypoglycaemia
Number of subjects: 370
Study 22476616 — intervention group
Group type: COMPARATOR
Intervention: Thiazolidinediones
Number of subjects: 370
Study 19683414 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder Pain and Disability Index (SPADI)
Number of subjects: 0
Study 19683414 — intervention group
Group type: EXPERIMENTAL
Intervention: Croft Index
Number of subjects: 0
Study 19683414 — intervention group
Group type: EXPERIMENTAL
Intervention: Disabilities of the Arm, Shoulder, and Hand (DASH)
Number of subjects: 0
Study 19683414 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale for pain
Number of subjects: 0
Study 19683414 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Assessment Questionnaire
Number of subjects: 0
Study 19683414 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-elicitation technique
Number of subjects: 0
Study 18243498 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 months adjuvant goserelin
Number of subjects: 1554
Study 18243498 — intervention group
Group type: COMPARATOR
Intervention: 4 months goserelin followed by no additional therapy
Number of subjects: 1554
Study 15683433 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg b.i.d.
Number of subjects: 72
Study 15683433 — intervention group
Group type: COMPARATOR
Intervention: Famotidine 20 mg b.i.d.
Number of subjects: 72
Study 12458242 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump technique
Number of subjects: 60
Study 12458242 — intervention group
Group type: COMPARATOR
Intervention: On-pump technique
Number of subjects: 60
Study 10621921 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium alginate (Gaviscon Advance)
Number of subjects: 100
Study 10621921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 7733122 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 200 mg
Number of subjects: 290
Study 7733122 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolbutamide 250 to 1,000 mg
Number of subjects: 290
Study 7733122 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose-plus-tolbutamide
Number of subjects: 290
Study 7733122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 1914055 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg nalbuphine after lidocaine anaesthesia
Number of subjects: 58
Study 1914055 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nalbuphine after lidocaine anaesthesia
Number of subjects: 58
Study 1914055 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg nalbuphine after lidocaine anaesthesia
Number of subjects: 58
Study 1914055 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg nalbuphine after 2-chloroprocaine anaesthesia
Number of subjects: 58
Study 1914055 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nalbuphine after 2-chloroprocaine anaesthesia
Number of subjects: 58
Study 1914055 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg nalbuphine after 2-chloroprocaine anaesthesia
Number of subjects: 58
Study 1914055 — intervention group
Group type: COMPARATOR
Intervention: lidocaine anaesthesia
Number of subjects: 58
Study 7327976 — intervention group
Group type: EXPERIMENTAL
Intervention: Training at 1.68 rad . s‐1
Number of subjects: 17
Study 7327976 — intervention group
Group type: EXPERIMENTAL
Intervention: Training at 4.19 rad . s‐1
Number of subjects: 17
Study 7327976 — intervention group
Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 17
Study 31283920 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT screening (LDCT)
Number of subjects: 24453
Study 31283920 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT screening (LDCT) in patients with COPD
Number of subjects: 24453
Study 29095274 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 60
Study 29095274 — intervention group
Group type: COMPARATOR
Intervention: Vacuum erectile device (VED)
Number of subjects: 60
Study 25694056 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (16 mg to 32 mg per day) in addition to routine standard of care
Number of subjects: 69
Study 25694056 — intervention group
Group type: COMPARATOR
Intervention: Routine standard of care other than ARBs or ACEIs
Number of subjects: 69
Study 24399285 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified aftercare (IG) following inpatient medical rehabilitation
Number of subjects: 422
Study 24399285 — intervention group
Group type: COMPARATOR
Intervention: Usual care (CG) following inpatient medical rehabilitation
Number of subjects: 422
Study 22074866 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading (IML) implants
Number of subjects: 12
Study 22074866 — intervention group
Group type: COMPARATOR
Intervention: Conventional loading implants
Number of subjects: 12
Study 19444561 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration therapy (1000 ml of oral rehydration solution)
Number of subjects: 50
Study 19444561 — intervention group
Group type: COMPARATOR
Intervention: Intravenous therapy (1000 ml of intravenous electrolyte solution)
Number of subjects: 50
Study 17314338 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir (500 mg twice daily)
Number of subjects: 136
Study 15198290 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (Genotropin, 1 mg/m2/day)
Number of subjects: 25
Study 15198290 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study 11438316 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone lozenge (1 mg)
Number of subjects: 10
Study 11438316 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel (1 mg)
Number of subjects: 10
Study 9593146 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg orally every 12 h for 10 days
Number of subjects: 24
Study 9593146 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg orally every 24 h for 10 days
Number of subjects: 24
Study 9593146 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clarithromycin and loratadine
Number of subjects: 24
Study 9593146 — intervention group
Group type: COMPARATOR
Intervention: All three regimens (clarithromycin, loratadine, combination)
Number of subjects: 24
Study 7874080 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN) 3-5 million units per day for 3 months
Number of subjects: 180
Study 7874080 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymomodulin 10 mg three times per week for 2 months
Number of subjects: 180
Study 7874080 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 180
Study 2896957 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment combined with fortnightly chemoprophylaxis with 'Maloprim' (pyrimethamine/dapsone)
Number of subjects: 0
Study 2896957 — intervention group
Group type: COMPARATOR
Intervention: Treatment of presumptive episodes of clinical malaria with chloroquine
Number of subjects: 0
Study 31296525 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 kV protocol for CT angiography
Number of subjects: 90
Study 31296525 — intervention group
Group type: COMPARATOR
Intervention: Automated tube voltage adaptation
Number of subjects: 90
Study 28097310 — intervention group
Group type: EXPERIMENTAL
Intervention: IVT and MT
Number of subjects: 291
Study 28097310 — intervention group
Group type: COMPARATOR
Intervention: MT
Number of subjects: 291
Study 25572706 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen 50 mg/day
Number of subjects: 64
Study 25572706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 23991838 — intervention group
Group type: EXPERIMENTAL
Intervention: Early BCG vaccination
Number of subjects: 281
Study 23991838 — intervention group
Group type: COMPARATOR
Intervention: Delayed BCG vaccination
Number of subjects: 281
Study 23991838 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination with scar
Number of subjects: 281
Study 23991838 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 281
Study 23991838 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation with simultaneous BCG
Number of subjects: 281
Study 21813807 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTM1-0 genotype
Number of subjects: 383
Study 21813807 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTT1-0 genotype
Number of subjects: 383
Study 21813807 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTM1-0/GSTT1-0 (n = 37)
Number of subjects: 383
Study 21813807 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotenoids and α- and γ-tocopherols
Number of subjects: 383
Study 19433149 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential self-focus (concrete, process-focused)
Number of subjects: 82
Study 19433149 — intervention group
Group type: EXPERIMENTAL
Intervention: Analytical self-focus (abstract, evaluative)
Number of subjects: 82
Study 16679630 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous L-carnitine 20 mg/kg after every dialysis session for 8 weeks
Number of subjects: 20
Study 16679630 — intervention group
Group type: COMPARATOR
Intervention: Placebo after every dialysis session for 8 weeks
Number of subjects: 20
Study 15090626 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 g of high oleic acid sunflower oil)
Number of subjects: 81
Study 15090626 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g of cis‐9,trans‐11 (c9t11) CLA
Number of subjects: 81
Study 15090626 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of cis‐9,trans‐11 (c9t11) CLA
Number of subjects: 81
Study 15090626 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g of trans‐10,cis‐12 (t10c12) CLA
Number of subjects: 81
Study 15090626 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of trans‐10,cis‐12 (t10c12) CLA
Number of subjects: 81
Study 10856731 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (mean final dosage 135 mg/day)
Number of subjects: 52
Study 10856731 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 52
Study 10856731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 9355892 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (200 mg TID)
Number of subjects: 48
Study 9355892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 8471413 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg)
Number of subjects: 12
Study 8471413 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg)
Number of subjects: 12
Study 8471413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8471413 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine and Ranitidine
Number of subjects: 12
Study 3890036 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine carbonate (1% solution)
Number of subjects: 40
Study 3890036 — intervention group
Group type: COMPARATOR
Intervention: Mepivacaine hydrochloride (1% solution)
Number of subjects: 40
Study 3890036 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine carbonate
Number of subjects: 40
Study 3890036 — intervention group
Group type: COMPARATOR
Intervention: Mepivacaine hydrochloride
Number of subjects: 40
Study 31324175 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial micro-incentive (food voucher)
Number of subjects: 45
Study 31324175 — intervention group
Group type: EXPERIMENTAL
Intervention: Male-targeted HIV specific decision support (EPIC-HIV)
Number of subjects: 45
Study 31324175 — intervention group
Group type: EXPERIMENTAL
Intervention: Both micro-incentives and male-targeted decision support
Number of subjects: 45
Study 31324175 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 45
Study 28391756 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanger sequencing and minisequencing
Number of subjects: 166
Study 28391756 — intervention group
Group type: EXPERIMENTAL
Intervention: Length heteroplasmy (LH)
Number of subjects: 166
Study 28391756 — intervention group
Group type: EXPERIMENTAL
Intervention: Point mutation heteroplasmy (PMH)
Number of subjects: 166
Study 25865740 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual preconditioning (video with pre-recorded commentary)
Number of subjects: 0
Study 25865740 — intervention group
Group type: COMPARATOR
Intervention: Control group (no audiovisual preconditioning)
Number of subjects: 0
Study 23643011 — intervention group
Group type: EXPERIMENTAL
Intervention: Cookgas intubating laryngeal airway (CILA)
Number of subjects: 86
Study 23643011 — intervention group
Group type: COMPARATOR
Intervention: Fastrach intubating laryngeal mask airway (FT‐LMA)
Number of subjects: 86
Study 23643011 — intervention group
Group type: COMPARATOR
Intervention: FT‐LMA
Number of subjects: 86
Study 23643011 — intervention group
Group type: EXPERIMENTAL
Intervention: CILA and FT‐LMA
Number of subjects: 86
Study 21247967 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine-doxorubicin-dexamethasone
Number of subjects: 33
Study 21247967 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan-prednisolone
Number of subjects: 33
Study 20306937 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement of hospital chaplains in spiritual care during treatment.
Number of subjects: 0
Study 20306937 — intervention group
Group type: COMPARATOR
Intervention: Standard care without chaplain involvement.
Number of subjects: 0
Study 17761574 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to acts of terrorism
Number of subjects: 960
Study 17761574 — intervention group
Group type: COMPARATOR
Intervention: Posttraumatic stress and depressive symptoms (controlled for)
Number of subjects: 960
Study 15066900 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplant
Number of subjects: 30
Study 15066900 — intervention group
Group type: COMPARATOR
Intervention: Sham Surgery
Number of subjects: 30
Study 11223765 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based intervention (prevention group)
Number of subjects: 542
Study 11223765 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 542
Study 7921428 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 60
Study 7921428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 3045099 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 60
Study 3045099 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 60
Study 31144057 — intervention group
Group type: EXPERIMENTAL
Intervention: Video group
Number of subjects: 91
Study 31144057 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 91
Study 28973430 — intervention group
Group type: EXPERIMENTAL
Intervention: Antecedent hypoglycemia (3 periods of 45 minutes at 2.8 mmol/L)
Number of subjects: 10
Study 28973430 — intervention group
Group type: COMPARATOR
Intervention: Control (3 periods of 45 minutes at 6 mmol/L)
Number of subjects: 10
Study 25932792 — intervention group
Group type: EXPERIMENTAL
Intervention: ERN (2g/day)
Number of subjects: 56
Study 25932792 — intervention group
Group type: EXPERIMENTAL
Intervention: Combo therapy (ERN + P-OM3)
Number of subjects: 56
Study 25932792 — intervention group
Group type: EXPERIMENTAL
Intervention: P-OM3 (4g/day)
Number of subjects: 56
Study 25932792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 23548121 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) group
Number of subjects: 0
Study 23548121 — intervention group
Group type: COMPARATOR
Intervention: Sham electro-acupuncture (SA) group
Number of subjects: 0
Study 21246465 — intervention group
Group type: EXPERIMENTAL
Intervention: Alarm-clock set at 2 h intervals for glucose self monitoring
Number of subjects: 30
Study 21246465 — intervention group
Group type: COMPARATOR
Intervention: Nurse performing blood glucose determinations
Number of subjects: 30
Study 21246465 — intervention group
Group type: COMPARATOR
Intervention: Patients left undisturbed
Number of subjects: 30
Study 18342395 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory education program with 12 sessions of taste lessons 'Les classes du goût' by J. Puisais
Number of subjects: 180
Study 18342395 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sensory education)
Number of subjects: 180
Study 18342395 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory education program
Number of subjects: 180
Study 16861099 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg QD
Number of subjects: 46
Study 16861099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 12963170 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-conjugated oestrogen 0.625 mg daily (n=13)
Number of subjects: 23
Study 12963170 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestrogen patches 50 microg daily (n=10)
Number of subjects: 23
Study 10720589 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg for 1 month)
Number of subjects: 23
Study 10720589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 9418383 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger adults
Number of subjects: 371
Study 9418383 — intervention group
Group type: COMPARATOR
Intervention: Elderly adults
Number of subjects: 371
Study 9418383 — intervention group
Group type: EXPERIMENTAL
Intervention: Testimony from elderly witnesses (manipulated to appear as younger)
Number of subjects: 371
Study 9418383 — intervention group
Group type: EXPERIMENTAL
Intervention: Testimony from younger witnesses (manipulated to appear as older)
Number of subjects: 371
Study 9418383 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcribed testimonies from Experiment 1 participants
Number of subjects: 371
Study 8131394 — intervention group
Group type: EXPERIMENTAL
Intervention: U technique
Number of subjects: 76
Study 8131394 — intervention group
Group type: COMPARATOR
Intervention: Standard removal technique
Number of subjects: 76
Study 3299567 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol retard (75 mg)
Number of subjects: 214
Study 3299567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 29065710 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoghurt drink containing Lactobacillus strains (125 g, twice daily for 4 weeks)
Number of subjects: 36
Study 29065710 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoghurt drink containing Lactobacillus strains
Number of subjects: 36
Study 29065710 — intervention group
Group type: COMPARATOR
Intervention: Placebo (125 g chemically acidified milk, twice daily for 4 weeks)
Number of subjects: 36
Study 29065710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 27609384 — intervention group
Group type: EXPERIMENTAL
Intervention: Sof‐lex discs system
Number of subjects: 150
Study 27609384 — intervention group
Group type: EXPERIMENTAL
Intervention: Super‐snap system
Number of subjects: 150
Study 27609384 — intervention group
Group type: COMPARATOR
Intervention: diamond bur and rubber cup
Number of subjects: 150
Study 26346155 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalent HPV vaccination (n=3727)
Number of subjects: 7466
Study 26346155 — intervention group
Group type: COMPARATOR
Intervention: hepatitis A vaccine (n=3739)
Number of subjects: 7466
Study 26346155 — intervention group
Group type: COMPARATOR
Intervention: unvaccinated cohort (n=2836)
Number of subjects: 7466
Study 23607963 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical vitamin E once daily
Number of subjects: 80
Study 23607963 — intervention group
Group type: COMPARATOR
Intervention: Emollient once daily
Number of subjects: 80
Study 21555965 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral needle approach
Number of subjects: 80
Study 21555965 — intervention group
Group type: COMPARATOR
Intervention: Medial needle approach
Number of subjects: 80
Study 18794002 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorative proctocolectomy
Number of subjects: 0